Cardiac Drug Safety
Screening Platform
Predict Torsades de Pointes risk using FDA-endorsed CiPA methodology. O'Hara-Rudy cardiac cell simulation combined with machine learning for instant, validated drug safety assessment.
Industry-Grade Cardiac Safety Screening
Everything you need for CiPA-compliant in silico proarrhythmia risk assessment, at a fraction of the cost of legacy enterprise tools.
Custom Compound Screening
Input IC50 values for 7 ion channels. Get instant TdP risk prediction with full AP waveform analysis.
O'Hara-Rudy Simulation
FDA-endorsed CiPA cardiac cell model. 500-beat pre-pacing, 6 ion currents, qNet charge integral.
ML Risk Classification
Gradient boosted machine trained on 28 CiPA reference drugs. AUC = 0.860 on held-out drug split.
28-Drug Reference Database
Complete CiPA training set with pre-computed simulations, ion current profiles, and risk benchmarks.
Transparent Validation
Full confusion matrix, ROC curves, per-drug classification results. Nothing hidden.
PDF Reports
Download regulatory-ready reports with simulation parameters, results, and methodology.
Ready to screen your compounds?
Start with the 28 CiPA reference drugs or bring your own IC50 data for instant cardiac safety predictions.
Screen a Custom Compound